000 01382 a2200373 4500
005 20250515032337.0
264 0 _c20061204
008 200612s 0 0 eng d
022 _a0277-0008
024 7 _a10.1592/phco.26.7.903
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBeumer, Jan H
245 0 0 _aDisposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
_h[electronic resource]
260 _bPharmacotherapy
_cJul 2006
300 _a903-7 p.
_bdigital
500 _aPublication Type: Case Reports; Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650 0 4 _aAntineoplastic Agents
_xblood
650 0 4 _aBenzamides
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImatinib Mesylate
650 0 4 _aJejunostomy
650 0 4 _aLeukemia, Myelogenous, Chronic, BCR-ABL Positive
_xdrug therapy
650 0 4 _aMiddle Aged
650 0 4 _aPiperazines
_xblood
650 0 4 _aPyrimidines
_xblood
650 0 4 _aShort Bowel Syndrome
_xmetabolism
700 1 _aNatale, James J
700 1 _aLagattuta, Theodore F
700 1 _aRaptis, Anastasios
700 1 _aEgorin, Merrill J
773 0 _tPharmacotherapy
_gvol. 26
_gno. 7
_gp. 903-7
856 4 0 _uhttps://doi.org/10.1592/phco.26.7.903
_zAvailable from publisher's website
999 _c16396421
_d16396421